TD Asset Management Inc Purchases 860 Shares of argenex SE $ARGX

TD Asset Management Inc boosted its position in shares of argenex SE (NASDAQ:ARGX) by 0.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,902 shares of the company’s stock after acquiring an additional 860 shares during the period. TD Asset Management Inc owned 0.20% of argenex worth $89,172,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. AQR Capital Management LLC raised its position in argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after purchasing an additional 1,431 shares during the last quarter. Focus Partners Wealth raised its holdings in shares of argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after buying an additional 73 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in shares of argenex by 550.0% during the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after acquiring an additional 99 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in argenex by 27.1% in the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,934 shares of the company’s stock worth $1,066,000 after purchasing an additional 412 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenex Stock Down 2.6%

Shares of ARGX opened at $818.46 on Thursday. The company has a market capitalization of $50.65 billion, a P/E ratio of 35.14, a price-to-earnings-growth ratio of 0.73 and a beta of 0.37. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The firm has a 50 day moving average of $829.64 and a 200 day moving average of $810.13.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. DZ Bank raised shares of argenex to a “strong-buy” rating in a report on Friday, December 19th. TD Cowen increased their price target on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. HC Wainwright raised their price objective on shares of argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Finally, Wedbush restated an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, argenex currently has an average rating of “Moderate Buy” and a consensus price target of $986.78.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.